CARLSBAD, Calif., July 31 /PRNewswire/ -- Excaliard Pharmaceuticals, a late stage preclinical company developing targeted therapeutics for the treatment of skin scarring and fibrotic disorders, is pleased to announce that Jay Birnbaum, Ph.D. has joined the Board of Directors as an Independent Board Member.
Dr. Jay Birnbaum is a dermatology consultant specializing in ethical and OTC drugs, medical devices, and cosmeceuticals. His 35 years of industry experience span the areas of discovery research, formulations, clinical R&D, regulatory and marketing, and he has been involved in the development and commercialization of numerous drug and consumer products and brands. Dr. Birnbaum is a co-founder and former Chief Medical Officer of Kythera Biopharmaceuticals, a company developing products in aesthetic dermatology. Prior to starting his own consulting company in 1999, he was with Novartis/Sandoz Pharmaceuticals Corporation, serving most recently as Vice President, Global Project Management, with responsibilities for strategic planning and development of the company's dermatology portfolio. Prior to that, Dr. Birnbaum held various management positions at the Medical and Consumer Product Divisions of American Cyanamid Company (Wyeth).
Dr. Birnbaum has broad relationships in industry and academia, and has published extensively on his work in drug development. His professional affiliations include the American Academy of Dermatology, Society of Investigative Dermatology, European Academy of Dermatology and Venereology, American Society for Dermatologic Surgery, and International Society of Dermatology. He is a member of the board of directors of Oculus Innovative Sciences, Inc. and is on the Science Advisory Boards of Evolva, NanoBio Corp, NexMed, Inc., Topica Pharmaceuticals, and Transport Pharmaceuticals.
He received a B.S. degree from Trinity College and a Ph.D in Pharmacology from the University of Wisconsin.
Excaliard Pharmaceuticals, Inc,(R) is delighted to have an individual with Jay's technical and business experience join the Board of Directors and looks forward to his many contributions.
|SOURCE Excaliard Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved